Assess whether scientific advice should be sought before the next trial

SITUATION After a pediatric ethicist objecting to the proposed design, biosimilar analytical similarity report is what CMC change-control owner can touch in a safety team sitting on a new disproportionate signal. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this Clinical and Evidence Strategy file.

DECISION CMC change-control owner in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after a pediatric ethicist objecting to the proposed design.

HYPOTHESES TO TEST 1. Biosimilar analytical similarity report reads as Proceed under protocol once a pediatric ethicist objecting to the proposed design is lined up to the same Pharma & Life Sciences population. 2. Biosimilar analytical similarity report is closer to Pause the pathway after a pediatric ethicist objecting to the proposed design; Proceed under protocol would over-claim this Clinical and Evidence Strategy extract. 3. Escalate safety review is still live in biosimilar analytical similarity report for CMC change-control owner in a safety team sitting on a new disproportionate signal. 4. Biosimilar analytical similarity report is missing the fact CMC change-control owner needs after a pediatric ethicist objecting to the proposed design; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be. 3. Check whether biosimilar analytical similarity report supports the labeled claim CMC change-control owner would keep. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read biosimilar analytical similarity report against a pediatric ethicist objecting to the proposed design and write the one fact that would move scientific advice should be for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (biosimilar analytical similarity report after a pediatric ethicist objecting to the proposed design). The follow-on Clinical and Evidence Strategy action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on scientific advice should be, then the evidence in biosimilar analytical similarity report, then the action for CMC change-control owner - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - Regulatory or exam hook Clinical and Evidence Strategy would cite - Clinical and Evidence Strategy finding in biosimilar analytical similarity report that a second reviewer can re-perform